NRx Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGNRx Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings contraction of 80% provides fundamental context to the price action. However, price is extended 32% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.79 | +9.34% | ABOVE |
| 50 SMA | $2.31 | +32.29% | ABOVE |
| 100 SMA | $2.23 | +36.81% | ABOVE |
| 150 SMA | $2.41 | +26.46% | ABOVE |
| 200 SMA | $2.50 | +21.93% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NRXP in an uptrend right now?
NRXP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NRXP overbought or oversold?
NRXP's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is NRXP outperforming the market?
NRXP has a Relative Strength (RS) Rating of 85 out of 99. Yes, NRXP is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is NRXP in its 52-week range?
NRXP is trading at $3.05, which is 79% of its 52-week high ($3.84) and 64% above its 52-week low ($1.62).
How volatile is NRXP?
NRXP has a Beta of 1.91 and 52-week volatility of 82%. It's more volatile than the S&P 500 - expect bigger swings.